Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in
AstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an irritable bowel syndrome drug in
Patients in Scotland will gain access to Vertex’s cystic fibrosis drugs Orkambi and Symkevi, after the company signed an access agreement with health officials.
